{
    "clinical_study": {
        "@rank": "80558", 
        "arm_group": [
            {
                "arm_group_label": "Icotinib", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery."
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the overall response rate and disease free survival\n      for IIIAN2 non-small-cell lung cancer patients with EGFR 19 or 21 exon mutation."
        }, 
        "brief_title": "Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small-cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Neoadjuvant therapy has been used for years to treat patients with non-small-cell lung\n      cancer whose primary tumors are too large to allow for surgery. Reduction in size of the\n      primary tumor with neoadjuvant therapy has made it possible for those patients. Moreover,\n      the goals have expanded to include: determination of the sensitivity of the tumor so that\n      subsequent therapy can be modified accordingly; to prolong disease free survival; to prolong\n      survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1.The patients signed the written informed consent. 2.The patients present with\n             operable IIIAN2 non-small-cell lung cancers with 19 or 21 exon mutation.\n\n             3.The patients have no history of anti-cancer therapies including chemotherapy,\n             radiation therapy, and surgical therapy.\n\n             4.The patients' Eastern Cooperative Oncology Group scores are \u2264 0-1. 5.The age of\n             patient is \u2265 18 years old with a life expectancy longer than 3 months.\n\n        Exclusion Criteria:\n\n          -  1. Patients with unresected tumor. 2. Wild EGFR type. 3. Allergic to the study drug.\n             4. Patients have severe non-cancerous diseases. 5. Patients are undergoing current\n             administration of anti-cancer therapies, or are attending some other clinical trials."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843647", 
            "org_study_id": "BD-IC-IV06"
        }, 
        "intervention": [
            {
                "arm_group_label": "Icotinib", 
                "description": "Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.", 
                "intervention_name": "Icotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Commana", 
                    "BPI-2009"
                ]
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "description": "After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine\n/cisplatin regimen, until untolerable toxicity or disease progression.", 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Vinorelbine", 
                    "Cisplatin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vinorelbine", 
                "Cisplatin", 
                "Mitogens"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310022"
                }, 
                "name": "Zhejiang cancer hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Controlled, Multicenter Study of Neoadjuvant Therapy With Icotinib in IIIA NSCLC Patients With Epidermal Growth Factor Receptor Mutation", 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "Weimin Mao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "CFDA: China Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Disease free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843647"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The pathological complete response rate after neoadjuvant therapy with icotinib", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "The lymph node staging reduction rate of patients after neoadjuvant therapy with icotinib", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "The resection rate of patients after neoadjuvant therapy with icotinib", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}